On June 5, 2017, WIRED prominently spotlighted AFAR Deputy Scientific Director Nir Barzilai, MD and the AFAR-managed TAME trial.
The feature story, Forget the Blood of Teens. This Pill Promises to Extend Life for a Nickel a Pop, describes the history of metformin, how the drug works inside our cells, and the state of moving metformin into clinical trials.
The article also stresses the fundraising—from a mix of NIH and private donations--necessary to advance this groundbreaking project and reminds of the project’s larger goal of providing proof-of-concept to the FDA to consider aging an indication for future drugs.
Dr. Barzilai suggests TAME is innovative from the current ineffective approach of treating each age-related illness separately. He explains: “Unless we target aging itself, all we can hope is that we switch one disease for another.”
The full article can be read here.
Nir Barzilai, MD is the Director of the Institute for Aging Research at Albert Einstein College of Medicine and the Director of the Nathan Shock Centers of Excellence in the Biology of Aging at Albert Einstein College of Medicine.
For more information on the TAME Trial, we encourage you to view our TAME Trial FAQ page here.
